Effect of simvastatin on hemostasis in <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">isolated_3</font> <font color="blue">hypertriglyceridemia_3</font> <font color="blue">._3</font> 
<br>
<br> BACKGROUNDS / AIMS Elevated triglyceride levels seem to predispose to the earlier development and accelerated progression of coronary artery disease . In our study , we assessed for the first time whether simvastatin treatment affects coagulation and fibrinolysis in <font color="blue">patients_2</font> <font color="blue">with_2</font> <font color="blue">isolated_2</font> <font color="blue">hypertriglyceridemia_2</font> <font color="blue">._2</font> 
<br> METHODS The <font color="blue">study_1</font> <font color="blue">included_1</font> <font color="blue">39_5</font> <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">elevated_5</font> <font color="blue">triglyceride_5</font> <font color="blue">levels_5</font> <font color="blue">and_5</font> <font color="blue">peripheral_5</font> <font color="blue">artery_5</font> <font color="blue">sclerosis_5</font> <font color="blue">,_5</font> <font color="blue">treated_2</font> <font color="blue">for_2</font> <font color="blue">90_2</font> <font color="blue">days_2</font> <font color="blue">with_2</font> <font color="blue">either_2</font> <font color="blue">simvastatin_2</font> <font color="blue">(_2</font> <font color="blue">40_2</font> <font color="blue">mg_2</font> <font color="blue">daily_2</font> <font color="blue">)_2</font> <font color="blue">or_2</font> <font color="blue">placebo_2</font> <font color="blue">._1</font> Plasma lipids , glucose homeostasis markers and hemostasic variables were assessed at baseline and after treatment . 
<br> RESULTS Simvastatin , but not placebo , administered to these patients reduced plasma levels / activity of fibrinogen ( from 3.5 ± 0.4 to 2.8 ± 0.3 g / l , p < 0.01 ) , factor VII ( from 144.2 ± 16.9 to 112.5 ± 14.0% , p < 0.01 ) and plasminogen activator inhibitor-1 ( from 76.9 ± 13.5 to 50.2 ± 9.2 ng / ml , p < 0.001 ) , without a significant reduction in von Willebrand factor levels , and tended to prolong the prothrombin and partial thromboplastin times . 
<br> CONCLUSION Our results suggest that statin treatment produces a multidirectional effect on coagulation and fibrinolysis in <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">isolated_1</font> <font color="blue">hypertriglyceridemia_1</font> and that this treatment may bring some benefits to <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">elevated_1</font> <font color="blue">triglyceride_1</font> <font color="blue">levels_1</font> <font color="blue">._1</font>